Incyte Corporation (INCY) is a biopharmaceutical company valued at $16.7 billion, specializing in therapeutics for hematology/oncology and other areas. INCY stock has outperformed the S&P 500 and iShares Biotechnology ETF over the past year, with YTD gains of 23.7%. Strong sales of Jakafi and new FDA approvals contributed to its success.

After reporting Q2 results, INCY shares surged over 10%, with adjusted EPS of $1.57 beating expectations. Revenue reached $1.22 billion, exceeding forecasts. Analysts expect INCY’s EPS to grow significantly to $5.06 for the current fiscal year. The consensus rating among 27 analysts covering INCY is a “Moderate Buy.”

Analyst Marc Frahm from TD Cowen maintains a “Buy” rating on INCY with a price target of $89, implying a 4.1% upside potential. Despite trading above the mean price target of $82.45, the Street-high target of $110 suggests a 28.7% potential increase. This bullish outlook reflects INCY’s strong performance and growth prospects in the pharmaceutical industry.

Read more at Yahoo Finance: Are Wall Street Analysts Predicting Incyte Stock Will Climb or Sink?